350 related articles for article (PubMed ID: 29694241)
21. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
[TBL] [Abstract][Full Text] [Related]
22. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
23. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
25. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
27. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
Cardo E; Porsdal V; Quail D; Fuentes J; Steer C; Montoya A; Anand E; Escobar R
J Child Adolesc Psychopharmacol; 2013 May; 23(4):252-61. PubMed ID: 23683140
[TBL] [Abstract][Full Text] [Related]
28. The quantified EEG characteristics of responders and non-responders to long-term treatment with atomoxetine in children with attention deficit hyperactivity disorders.
Chiarenza GA; Chabot R; Isenhart R; Montaldi L; Chiarenza MP; Torto MG; Prichep LS
Int J Psychophysiol; 2016 Jun; 104():44-52. PubMed ID: 27108364
[TBL] [Abstract][Full Text] [Related]
29. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
30. Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Shih HH; Pan YL; Lin HY; Gau SS
J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):148-158. PubMed ID: 31794244
[No Abstract] [Full Text] [Related]
31. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
Upadhyaya H; Kratochvil C; Ghuman J; Camporeale A; Lipsius S; D'Souza D; Tanaka Y
J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):799-809. PubMed ID: 25265343
[TBL] [Abstract][Full Text] [Related]
33. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
Asherson P; Bushe C; Saylor K; Tanaka Y; Deberdt W; Upadhyaya H
J Psychopharmacol; 2014 Sep; 28(9):837-46. PubMed ID: 25035246
[TBL] [Abstract][Full Text] [Related]
36. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
[TBL] [Abstract][Full Text] [Related]
37. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
Martenyi F; Zavadenko NN; Jarkova NB; Yarosh AA; Soldatenkova VO; Bardenstein LM; Kozlova IA; Neznanov NG; Maslova OI; Petrukhin AS; Sukchotina NK; Zykov VP
Eur Child Adolesc Psychiatry; 2010 Jan; 19(1):57-66. PubMed ID: 19568826
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
39. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
[TBL] [Abstract][Full Text] [Related]
40. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
Shaywitz S; Shaywitz B; Wietecha L; Wigal S; McBurnett K; Williams D; Kronenberger WG; Hooper SR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):19-28. PubMed ID: 27410907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
